Diligence Requirements. During the Term and following [[MyoKardia:Organization]]’s designation of the Lead Cardiomyopathy Target, [[MyoKardia:Organization]] will use Commercially Reasonable Efforts to advance ​ Product to Regulatory Approval ​. After receiving Regulatory Approval for a Product ​, [[MyoKardia:Organization]] will use Commercially Reasonable Efforts to commercialize such Product in ​. After receiving Regulatory Approval for a Product ​, [[MyoKardia:Organization]] will use Commercially Reasonable Efforts to commercialize such Product ​. Subject to [Section 3.7] (Subcontracting) with respect to [[MyoKardia:Organization]]’s responsibilities under the Research Plan, [[MyoKardia:Organization]] may satisfy its obligations under this Section 4.2 (Diligence Requirements) itself or through one or more Affiliates or Third Parties selected by [[MyoKardia:Organization]] in its sole discretion.

Diligence Requirements. During the Term and following Acceleron’s designation of the first ​ Target, Acceleron will use Commercially Reasonable Efforts to research, develop and seek Regulatory Approval for and, solely to the extent necessary to seek such Regulatory Approval, manufacture or have manufactured one (1) Product in the Major Market Countries. After receiving Regulatory Approval for a Product in any Major Market Country, Acceleron will use Commercially Reasonable Efforts to commercialize such Product in each such Major Market Country. Subject to [Section 3.4] (Subcontracting), Acceleron may satisfy its obligations under this [Section 4.6] (Diligence Requirements) itself or through one or more Affiliates or Third Parties selected by Acceleron in its sole discretion. Following designation by Acceleron of the first ​ Target, Acceleron shall provide a written report to Fulcrum within ​ after ​ of each year during the Term that summarizes Acceleron’s exercise of efforts with respect to the research, development and commercialization of Products under this Agreement, including matters relating to seeking Regulatory Approval therefor. Notwithstanding anything to the contrary in this Agreement (including this [Section 4.6] (Diligence Requirements)), Acceleron will have no obligation to negotiate agreements to obtain additional rights to satisfy its obligations in this [Section 4.6] (Diligence Requirements).

Diligence Requirements. Licensee shall use, and shall cause its Affiliates and Sublicensees, as applicable, to use, Commercially Reasonable Efforts to develop and make available to the public at least one Product or Processes in the License Territory in the License Field Such efforts shall include achieving the requirements set forth in the table below by the dates specified in the table below.

Diligence. On a Research Program-by-Research Program basis, during the applicable Research Term, Stoke shall conduct the Research Program in accordance with this Agreement. Without limiting the foregoing, on a Research Plan-by-Research Plan basis, Stoke shall use Commercially Reasonable Efforts to conduct (itself or through its Affiliates or by permitted subcontracting) its obligations under such Research Plan in accordance with the timeframes set forth therein. Stoke shall conduct each Research Program in a good scientific manner, in accordance with GLP, GMP and GCP, as applicable, and in compliance with Applicable Laws. For clarity, for a given Research Program, Stoke shall not be required to perform any work which is not included in the applicable then-current Research Plan and corresponding Research Budget approved in accordance with this Agreement.

Diligence. Licensee will use Commercially Reasonable Efforts to Develop (including filing NDAs and seeking Regulatory Approval) at least one Product in the Field in ​. Following receipt of Regulatory Approval in any such countries, Licensee will use Commercially Reasonable Efforts to Commercialize at least one Product in the Field in such countries.

Diligence. Following receipt of Regulatory Approval for a Licensed Product in a Major Market, Acadia (and its Affiliates and Sublicensees, as applicable) shall use Commercially Reasonable Efforts to ​. Acadia shall conduct all such Commercialization in a good scientific manner, in accordance with GLP, GMP and GCP, as applicable, and in compliance with Applicable Laws.

Diligence Requirements. Licensee shall use, and shall cause its Affiliates and Sublicensees, as applicable, to use, Commercially Reasonable Efforts to develop and make available to the public at least one Product or Processes in the License Territory in the License Field Such efforts shall include achieving the requirements set forth in the table below by the dates specified in the table below.

Diligence. Each Party shall use Commercially Reasonable Efforts to conduct (itself or through its Affiliates or by permitted subcontracting) the activities assigned to it under the then-current [[Unknown Identifier]] Co-Development Plan in accordance with the timeframes set forth therein. Each Party shall conduct such activities in a good scientific manner, in accordance with GLP, GMP and GCP, as applicable, and in compliance with Applicable Laws. All Development activities (other than those activities set forth in the [[Unknown Identifier]] Research Plan), including Clinical Trials, for [[Unknown Identifier]] Co-Co Products in the Territory shall be conducted solely as set forth in the relevant [[Unknown Identifier]] Co-Development Plan, and the Parties shall not perform any Development activities in the Territory for any [[Unknown Identifier]] Co-Co Product other than those set forth in the applicable [[Unknown Identifier]] Co-Development Plan. In the event a Party wishes to conduct a Development activity with respect to a [[Unknown Identifier]] Co-Co Product that is not included in the current applicable [[Unknown Identifier]] Co-Development Plan or [[Unknown Identifier]] Research Plan, e.g., with respect to a new formulation or indication, then such Party may propose such new Development activity to the JDC for consideration.

Diligence. Each Party shall use Commercially Reasonable Efforts to conduct the Research Collaboration by performing the activities allocated to such Party pursuant to this Agreement and the Development Plan (including any activities relating to New Research Programs that the Parties mutually agree to include within the scope of the Research Collaboration).

Diligence. With respect to each Development Program for [[Unknown Identifier]] and ​ Targets, Acadia shall use Commercially Reasonable Efforts to ​. On a Development Program-by-Development Program basis, Acadia shall use Commercially Reasonable Efforts to conduct (itself or through its Affiliates or Sublicensees) such Development Program in accordance with the Development Plan, including the timeframes set forth therein. Acadia shall conduct each Development Program in a good scientific manner, in accordance with GLP, GMP and GCP, as applicable, and in compliance with Applicable Laws.